Cholesterol, lipoproteins and subclinical interstitial lung disease: The MESA study

Anna J. Podolanczuk; Ganesh Raghu; Michael Y. Tsai; Steven M. Kawut; Eric Peterson; Rajiv Sonti; Daniel Rabinowitz; Craig Johnson; R. Graham Barr; Karen Hinckley Stukovsky; Eric A. Hoffman; J. Jeffrey Carr; Firas S. Ahmed; David R. Jacobs; Karol Watson; Steven J. Shea; David J. Lederer

doi:10.1136/thoraxjnl-2016-209568

Cholesterol, lipoproteins and subclinical interstitial lung disease: The MESA study

Anna J. Podolanczuk
, Ganesh Raghu
, Michael Y. Tsai
, Steven M. Kawut
, Eric Peterson
, Rajiv Sonti
, Daniel Rabinowitz
, Craig Johnson
, R. Graham Barr
, Karen Hinckley Stukovsky
, Eric A. Hoffman
, J. Jeffrey Carr
, Firas S. Ahmed
, David R. Jacobs
, Karol Watson
, Steven J. Shea
, David J. Lederer

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

We investigated associations of plasma lipoproteins with subclinical interstitial lung disease (ILD) by measuring high attenuation areas (HAA: lung voxels between -600 and -250 Hounsfield units) in 6700 adults and serum MMP-7 and SP-A in 1216 adults age 45-84 without clinical cardiovascular disease in Multi-Ethnic Study of Atherosclerosis. In cross-sectional analyses, each SD decrement in high density lipoprotein cholesterol (HDL-C) was associated with a 2.12% HAA increment (95% CI 1.44% to 2.79%), a 3.53% MMP-7 increment (95% CI 0.93% to 6.07%) and a 6.37% SP-A increment (95% CI 1.35% to 11.13%), independent of demographics, smoking and inflammatory biomarkers. These findings support a novel hypothesis that HDL-C might influence subclinical lung injury and extracellular matrix remodelling.

Original language	English (US)
Pages (from-to)	472-474
Number of pages	3
Journal	Thorax
Volume	72
Issue number	5
DOIs	https://doi.org/10.1136/thoraxjnl-2016-209568
State	Published - Jan 27 2017

Bibliographical note

Funding Information:
The work is funded by the National Institutes of Health contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 and grants UL1-TR-000040, UL1-TR-001079, R01-HL-103676, RC1-HL100543, R01-HL-093081, R01-HL-077612, T32-HL-105323 and K24-HL-131937; by the Pulmonary Fibrosis Foundation; and by the Rocco Guinta Research Fund.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1136/thoraxjnl-2016-209568

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388565

Find It

Find It at U of M Libraries

Cite this

Podolanczuk, A. J., Raghu, G., Tsai, M. Y., Kawut, S. M., Peterson, E., Sonti, R., Rabinowitz, D., Johnson, C., Barr, R. G., Stukovsky, K. H., Hoffman, E. A., Carr, J. J., Ahmed, F. S., Jacobs, D. R., Watson, K., Shea, S. J., & Lederer, D. J. (2017). Cholesterol, lipoproteins and subclinical interstitial lung disease: The MESA study. Thorax, 72(5), 472-474. https://doi.org/10.1136/thoraxjnl-2016-209568

Podolanczuk, AJ, Raghu, G, Tsai, MY, Kawut, SM, Peterson, E, Sonti, R, Rabinowitz, D, Johnson, C, Barr, RG, Stukovsky, KH, Hoffman, EA, Carr, JJ, Ahmed, FS, Jacobs, DR, Watson, K, Shea, SJ & Lederer, DJ 2017, 'Cholesterol, lipoproteins and subclinical interstitial lung disease: The MESA study', Thorax, vol. 72, no. 5, pp. 472-474. https://doi.org/10.1136/thoraxjnl-2016-209568

@article{b1d5b44a23ef4d01b3c1b491b87231c9,

title = "Cholesterol, lipoproteins and subclinical interstitial lung disease: The MESA study",

abstract = "We investigated associations of plasma lipoproteins with subclinical interstitial lung disease (ILD) by measuring high attenuation areas (HAA: lung voxels between -600 and -250 Hounsfield units) in 6700 adults and serum MMP-7 and SP-A in 1216 adults age 45-84 without clinical cardiovascular disease in Multi-Ethnic Study of Atherosclerosis. In cross-sectional analyses, each SD decrement in high density lipoprotein cholesterol (HDL-C) was associated with a 2.12\% HAA increment (95\% CI 1.44\% to 2.79\%), a 3.53\% MMP-7 increment (95\% CI 0.93\% to 6.07\%) and a 6.37\% SP-A increment (95\% CI 1.35\% to 11.13\%), independent of demographics, smoking and inflammatory biomarkers. These findings support a novel hypothesis that HDL-C might influence subclinical lung injury and extracellular matrix remodelling.",

author = "Podolanczuk, \{Anna J.\} and Ganesh Raghu and Tsai, \{Michael Y.\} and Kawut, \{Steven M.\} and Eric Peterson and Rajiv Sonti and Daniel Rabinowitz and Craig Johnson and Barr, \{R. Graham\} and Stukovsky, \{Karen Hinckley\} and Hoffman, \{Eric A.\} and Carr, \{J. Jeffrey\} and Ahmed, \{Firas S.\} and Jacobs, \{David R.\} and Karol Watson and Shea, \{Steven J.\} and Lederer, \{David J.\}",

note = "Funding Information: The work is funded by the National Institutes of Health contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 and grants UL1-TR-000040, UL1-TR-001079, R01-HL-103676, RC1-HL100543, R01-HL-093081, R01-HL-077612, T32-HL-105323 and K24-HL-131937; by the Pulmonary Fibrosis Foundation; and by the Rocco Guinta Research Fund.",

year = "2017",

month = jan,

day = "27",

doi = "10.1136/thoraxjnl-2016-209568",

language = "English (US)",

volume = "72",

pages = "472--474",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "5",

}

TY - JOUR

T1 - Cholesterol, lipoproteins and subclinical interstitial lung disease

T2 - The MESA study

AU - Podolanczuk, Anna J.

AU - Raghu, Ganesh

AU - Tsai, Michael Y.

AU - Kawut, Steven M.

AU - Peterson, Eric

AU - Sonti, Rajiv

AU - Rabinowitz, Daniel

AU - Johnson, Craig

AU - Barr, R. Graham

AU - Stukovsky, Karen Hinckley

AU - Hoffman, Eric A.

AU - Carr, J. Jeffrey

AU - Ahmed, Firas S.

AU - Jacobs, David R.

AU - Watson, Karol

AU - Shea, Steven J.

AU - Lederer, David J.

N1 - Funding Information: The work is funded by the National Institutes of Health contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 and grants UL1-TR-000040, UL1-TR-001079, R01-HL-103676, RC1-HL100543, R01-HL-093081, R01-HL-077612, T32-HL-105323 and K24-HL-131937; by the Pulmonary Fibrosis Foundation; and by the Rocco Guinta Research Fund.

PY - 2017/1/27

Y1 - 2017/1/27

N2 - We investigated associations of plasma lipoproteins with subclinical interstitial lung disease (ILD) by measuring high attenuation areas (HAA: lung voxels between -600 and -250 Hounsfield units) in 6700 adults and serum MMP-7 and SP-A in 1216 adults age 45-84 without clinical cardiovascular disease in Multi-Ethnic Study of Atherosclerosis. In cross-sectional analyses, each SD decrement in high density lipoprotein cholesterol (HDL-C) was associated with a 2.12% HAA increment (95% CI 1.44% to 2.79%), a 3.53% MMP-7 increment (95% CI 0.93% to 6.07%) and a 6.37% SP-A increment (95% CI 1.35% to 11.13%), independent of demographics, smoking and inflammatory biomarkers. These findings support a novel hypothesis that HDL-C might influence subclinical lung injury and extracellular matrix remodelling.

AB - We investigated associations of plasma lipoproteins with subclinical interstitial lung disease (ILD) by measuring high attenuation areas (HAA: lung voxels between -600 and -250 Hounsfield units) in 6700 adults and serum MMP-7 and SP-A in 1216 adults age 45-84 without clinical cardiovascular disease in Multi-Ethnic Study of Atherosclerosis. In cross-sectional analyses, each SD decrement in high density lipoprotein cholesterol (HDL-C) was associated with a 2.12% HAA increment (95% CI 1.44% to 2.79%), a 3.53% MMP-7 increment (95% CI 0.93% to 6.07%) and a 6.37% SP-A increment (95% CI 1.35% to 11.13%), independent of demographics, smoking and inflammatory biomarkers. These findings support a novel hypothesis that HDL-C might influence subclinical lung injury and extracellular matrix remodelling.

UR - https://www.scopus.com/pages/publications/85012024053

UR - https://www.scopus.com/pages/publications/85012024053#tab=citedBy

U2 - 10.1136/thoraxjnl-2016-209568

DO - 10.1136/thoraxjnl-2016-209568

M3 - Article

C2 - 28130491

AN - SCOPUS:85012024053

SN - 0040-6376

VL - 72

SP - 472

EP - 474

JO - Thorax

JF - Thorax

IS - 5

ER -

Cholesterol, lipoproteins and subclinical interstitial lung disease: The MESA study

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this